Skip to main content
Terug
XVIPY logo

Xvivo Perfusion AB (publ)

Datakwaliteit: 100%
XVIPY
OTC Healthcare Medical - Devices
€ 6,54
€ 0,00 (0,00%)
Marktkapitalisatie: 206,01M
Ook genoteerd als XVIPF OTC
Dagbereik
€ 6,54 € 6,54
52-Weeksbereik
€ 4,25 € 8,74
Volume
100
50D / 200D Gem.
€ 6,45 / € 6,45
Vorige Slotkoers
€ 6,54

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 1,2 0,3
P/B 0,1 2,9
ROE % 8,4 3,7
Net Margin % 20,9 3,8
Rev Growth 5Y % 46,2 10,0
D/E 0,0 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 € 0,00
€ 0,00 – € 0,00
 12 B 0
FY2026 € 0,00
€ 0,00 – € 0,00
 9,1 B 0

Belangrijkste Punten

Revenue grew 46,23% annually over 5 years — strong growth
Earnings grew 87,52% over the past year
Net margin of 20,94% shows strong profitability
Debt/Equity of 0,02 — conservative balance sheet
Generating 40,56M in free cash flow
P/E of 1,20 — trading at a low valuation

Groei

Revenue Growth (5Y)
46,23%
Revenue (1Y)37,63%
Earnings (1Y)87,52%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
8,40%
ROIC3,02%
Net Margin20,94%
Op. Margin10,74%

Veiligheid

Debt / Equity
0,02
Current Ratio4,58
Interest Coverage0,00

Waardering

P/E Ratio
1,20
P/B Ratio0,10
EV/EBITDA-1,99
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 37,63% Revenue Growth (3Y) 40,72%
Earnings Growth (1Y) 87,52% Earnings Growth (3Y) 205,68%
Revenue Growth (5Y) 46,23% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 822,42M Net Income (TTM) 172,18M
ROE 8,40% ROA 7,17%
Gross Margin 74,95% Operating Margin 10,74%
Net Margin 20,94% Free Cash Flow (TTM) 40,56M
ROIC 3,02% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,02 Current Ratio 4,58
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio 1,20 P/B Ratio 0,10
P/S Ratio 0,25 PEG Ratio 1,11
EV/EBITDA -1,99 Dividend Yield 0,00%
Market Cap 206,01M Enterprise Value -175,47M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 822,42M 597,54M 415,29M 258,39M 179,86M
Net Income 172,18M 91,82M 18,43M 8,15M -43,74M
EPS (Diluted) 1,36 0,77 0,16 0,07 -0,40
Gross Profit 616,42M 445,11M 296,96M 188,28M 132,98M
Operating Income 88,35M 4,19M 23,18M 6,98M -34,31M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 2,40B 2,20B 1,73B 1,54B 1,15B
Total Liabilities 245,97M 250,57M 302,95M 257,15M 141,85M
Shareholders' Equity 2,16B 1,95B 1,43B 1,29B 1,01B
Total Debt 34,04M 31,44M 10,01M 5,72M 7,21M
Cash & Equivalents 415,52M 545,79M 246,55M 398,70M 353,44M
Current Assets 813,08M 826,41M 467,51M 547,53M 463,23M
Current Liabilities 177,51M 134,49M 134,90M 104,52M 72,25M

Strategiescores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#801 of 827
10
Growth Price/Sales Ratio Focus (Ken Fisher)
#65 of 618
72
Value Defensive Investing (Benjamin Graham)
#509 of 709
17
Custom Full Throttle
#40 of 146
56

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026
Ingestapt Full Throttle
Mar 24, 2026